
Opinion|Videos|December 12, 2023
Managing Interstitial Lung Disease in Patients With HER2+ mCRC Receiving Trastuzumab Deruxtecan
Experts explore the management of interstitial lung disease in patients with colorectal cancer receiving treatment with trastuzumab deruxtecan and the consideration of liquid biopsies to assess HER2 status and adapt treatment strategies.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
4
What Does an End-of-Life Doula Do for Patients With Cancer?
5

























































